Richard M. Sherry

Richard M. Sherry publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Richard M. Sherry sits on this spectrum.

Richard M. Sherry D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Richard M. Sherry sits on this spectrum.

Best Publications

• Cancer regression in patients after transfer of genetically engineered lymphocytes

  Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  3824
  Citations

• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  3729
  Citations

• A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

  James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu

  3529
  Citations

• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

  Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  2587
  Citations

• Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

  Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

  2110
  Citations

• Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

  James N. Kochenderfer;Mark E. Dudley;Sadik H. Kassim;Robert P.T. Somerville

  2096
  Citations

• Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

  Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  1933
  Citations

• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  1911
  Citations

• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

  James N. Kochenderfer;Mark E. Dudley;Steven A. Feldman;Wyndham H. Wilson

  1741
  Citations

• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  Laura A. Johnson;Richard A. Morgan;Mark E. Dudley;Lydie Cassard

  1711
  Citations

• Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

  Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes

  1663
  Citations

• Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

  Richard E. Royal;Catherine Levy;Keli Turner;Aarti Mathur

  1537
  Citations

• Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

  Richard A. Morgan;Nachimuthu Chinnasamy;Daniel Abate-Daga;Alena Gros

  1512
  Citations

• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

  Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  1217
  Citations

• Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

  Peter Attia;Giao Q. Phan;Ajay V. Maker;Michael R. Robinson

  1146
  Citations

• The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

  Yair Herishanu;Patricia Pérez-Galán;Delong Liu;Angélique Biancotto

  1042
  Citations

• Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer

  James C. Yang;Richard M. Sherry;Seth M. Steinberg;Suzanne L. Topalian

  1001
  Citations

• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  James C. Yang;Marybeth Hughes;Udai Kammula;Richard E Royal

  979
  Citations

• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

  Kimberly E. Beck;Joseph A. Blansfield;Khoi Q. Tran;Andrew L. Feldman

  939
  Citations

• A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

  Paul F. Robbins;Sadik H. Kassim;Thai Lan N. Tran;Jessica S. Crystal

  889
  Citations